Inflammatory Rheumatism
15
3
5
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
85.7%
-0.8% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (15)
Treat-to-target by Email During Urate-lowering Therapy in Gout
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)
Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica
Mental Health Consequences of COVID19 Infection in the French RMD Cohort
Survey About Diet in Chronic Inflammatory Rheumatic Diseases
MST in Patients With Inflammatory Rheumatic Disease
Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia
HIIT for Inflammatory Rheumatic Disease: Man vs Machine
Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases